David J Cote1, Jordan H Creed2, Claudine M Samanic3, Travis A Gerke3, Meir J Stampfer4, Stephanie A Smith-Warner5, Kathleen M Egan3. 1. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: david_cote@hms.harvard.edu. 2. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States. Electronic address: Jordan.H.Creed@moffitt.org. 3. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States. 4. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Abstract
PURPOSE: The role of growth factors and inflammation in the onset of glioma is poorly understood, and conflicting reports of associations of circulating IGF-1 and inflammatory biomarkers with glioma risk exist in the literature. We examined associations between C-reactive protein (CRP), white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and insulin-like growth factor-1 (IGF-1) and glioma risk in the UK Biobank cohort. METHODS: Hazard ratios (HR) and 95% confidence intervals (CI) for glioma according to circulating biomarkers concentrations were calculated using Cox proportional hazards regression, adjusted for age, sex, race, and education. Analyses were conducted separately for glioma overall and by glioma subtype. RESULTS: We identified 417 incident glioma cases among 428,537 participants with 3,255,815 person-years of follow up. Weak, non-significant associations were observed with increasing levels of these biomarkers for risk of glioma overall or by glioma subtype. Among women only, IGF-1 in the highest quartile was positively associated with glioma risk compared to the lowest quartile (HR=1.64, 95%CI: 1.03-2.60, p-trend=0.08), as was NLR (HR=1.54, 95%CI: 1.00-2.39, p-trend=0.05). CONCLUSION: In this prospective cohort, we found no significant associations between the inflammatory biomarkers CRP and WBC and the development of glioma. NLR and IGF-1 were associated with risk in women, but not men. When considered with previous studies, further investigation of NLR and IGF-1 as markers of glioma risk appears warranted, particularly in women.
PURPOSE: The role of growth factors and inflammation in the onset of glioma is poorly understood, and conflicting reports of associations of circulating IGF-1 and inflammatory biomarkers with glioma risk exist in the literature. We examined associations between C-reactive protein (CRP), white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and insulin-like growth factor-1 (IGF-1) and glioma risk in the UK Biobank cohort. METHODS: Hazard ratios (HR) and 95% confidence intervals (CI) for glioma according to circulating biomarkers concentrations were calculated using Cox proportional hazards regression, adjusted for age, sex, race, and education. Analyses were conducted separately for glioma overall and by glioma subtype. RESULTS: We identified 417 incident glioma cases among 428,537 participants with 3,255,815 person-years of follow up. Weak, non-significant associations were observed with increasing levels of these biomarkers for risk of glioma overall or by glioma subtype. Among women only, IGF-1 in the highest quartile was positively associated with glioma risk compared to the lowest quartile (HR=1.64, 95%CI: 1.03-2.60, p-trend=0.08), as was NLR (HR=1.54, 95%CI: 1.00-2.39, p-trend=0.05). CONCLUSION: In this prospective cohort, we found no significant associations between the inflammatory biomarkers CRP and WBC and the development of glioma. NLR and IGF-1 were associated with risk in women, but not men. When considered with previous studies, further investigation of NLR and IGF-1 as markers of glioma risk appears warranted, particularly in women.
Authors: Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Devin C Koestler; Carmen J Marsit; Jennifer A Doherty; Laurie Grieshober; Stefan Graw; Matt J Barnett; Mark D Thornquist; Gary E Goodman; Chu Chen Journal: Cancer Prev Res (Phila) Date: 2018-09-25
Authors: Stefan Lönn; Peter D Inskip; Michael N Pollak; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Xiaoliang Wang; James Y Dai; Demetrius Albanes; Volker Arndt; Sonja I Berndt; Stéphane Bézieau; Hermann Brenner; Daniel D Buchanan; Katja Butterbach; Bette Caan; Graham Casey; Peter T Campbell; Andrew T Chan; Zhengyi Chen; Jenny Chang-Claude; Michelle Cotterchio; Douglas F Easton; Graham G Giles; Edward Giovannucci; William M Grady; Michael Hoffmeister; John L Hopper; Li Hsu; Mark A Jenkins; Amit D Joshi; Johanna W Lampe; Susanna C Larsson; Flavio Lejbkowicz; Li Li; Annika Lindblom; Loic Le Marchand; Vicente Martin; Roger L Milne; Victor Moreno; Polly A Newcomb; Kenneth Offitt; Shuji Ogino; Paul D P Pharoah; Mila Pinchev; John D Potter; Hedy S Rennert; Gad Rennert; Walid Saliba; Clemens Schafmayer; Robert E Schoen; Petra Schrotz-King; Martha L Slattery; Mingyang Song; Christa Stegmaier; Stephanie J Weinstein; Alicja Wolk; Michael O Woods; Anna H Wu; Stephen B Gruber; Ulrike Peters; Emily White Journal: Int J Epidemiol Date: 2019-06-01 Impact factor: 9.685